Arcus Biosciences (RCUS) Q3 2024 earnings summary

Executive summary

• Late-stage development of HIF-2alpha inhibitor casdatifan is prioritized, with strong efficacy and safety data in clear cell RCC, including a 34% ORR (25% confirmed) and 19% primary progression rate in heavily pretreated patients, outperforming current benchmarks.

• Domvanilimab plus zimberelimab demonstrated significant improvements in ORR, PFS, and OS in first-line PD-L1 high NSCLC, with a 36% reduction in risk of death and favorable safety profile.

• Multiple phase 3 trials are ongoing or planned, including PEAK-1 for casdatifan, STAR-121/STAR-221 for dom Zim in lung and gastric cancers, and PRISM-1 for quemliclustat in pancreatic cancer.

• Strategic collaborations with Gilead, Taiho, and AstraZeneca provide funding, resources, and expanded market access, with recent Taiho and AstraZeneca deals advancing key programs.

• The company operates as a single segment focused on immuno-oncology, targeting large addressable markets in NSCLC, RCC, gastric, pancreatic, and colorectal cancers.

Financial highlights

• Q3 2024 revenue was $48M, up from $39M in Q2 and $32M in Q3 2023, driven by collaboration milestones, Taiho opt-in, and a $107M Gilead agreement amendment.

• R&D expenses for Q3 2024 were $123M, up from $115M in Q2 and $82M in Q3 2023; G&A expenses remained flat at $30M.

• Net loss for Q3 2024 was $92M, compared to $71M in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $1.1B as of September 30, 2024, with a projected year-end balance of $950–$985M.

• Cash runway is expected to fund operations into mid-2027, supported by a $100M Gilead payment, $320M equity investment, and $50M term loan.

Outlook and guidance

• Additional ARC-20 data, including mature ORR and PFS, and initial data from new casdatifan cohorts are expected in 2025.

• PEAK-1 phase 3 trial for casdatifan in RCC to begin in H1 2025, targeting a $2B+ market in G7 countries.

• Gilead opt-in decision for casdatifan expected late 2024 or early 2025, with a $150M opt-in fee if exercised.

• Multiple phase 3 readouts anticipated in 2025, including STAR-221 (gastric cancer) and mature OS from EDGE-Gastric.

• The company anticipates continued operating losses as it advances late-stage clinical programs and expands its portfolio.